Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

15 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Multiple Myeloma · Phase 2 · Enrollment 30 · Sponsor: M.D. Anderson Cancer Center

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Cardiology on 15 Apr 2026. The item focuses on Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma. Open the detail page to review the full original feed content.